Beren Therapeutics secures $300 million to fund rare disease drug launch ahead of FDA review

Beren Therapeutics announced it has raised $300 million in new financing to support the development and launch of its rare disease therapy.

The funding arrives as the company prepares for an FDA decision expected later this year, positioning it to advance clinical work and commercial preparations.

The capital will be used to scale manufacturing, expand trial sites, and support regulatory activities as the drug moves toward market entry.